Sun Pharmaceutical Industries Ltd. sees a credit rating action

The exact quantum cannot be established from the cited material. The filing confirms that the Lipitor antitrust matter had been disclosed in Sun Pharma’s financial statements, but it does not reproduce the amount reported in the most recent Annual Report’s “Notes to Accounts” ^[1].

Likewise, the cited update does not state whether a claim-specific provision had been recognized in the balance sheet before the favourable appellate ruling. Accordingly, it would be unsafe to conclude either the amount or the provisioning position from this filing alone. The update only records that the Third Circuit affirmed summary judgment for Sun Pharma and its subsidiaries, substantially closing the litigation subject to any further remedies ^[1].

Expected treatment: the settled matter should not create a second “windfall” if the settlement liability was already fully provided. The provision would first be utilised against the settlement/payment; only any unused balance would be reversed through the statement of profit and loss. The exact line-item classification and whether it is presented as exceptional or operating income cannot be determined from the disclosed information.

The settlement became formally effective on 29 January 2026, after the deposited funds were transferred to the settlement fund ^[2]. Accordingly, the principal accounting impact should ordinarily have been captured in the financial statements covering that date, rather than first appearing in the next quarter.

For the contingent-liabilities note:

• If the obligation has been settled and no further exposure remains for that specific case, the item should be removed from the schedule or marked as settled.
• If Sun had only disclosed a contingent liability and had not recognised a provision, there would be no provision reversal or profit impact—only removal or updating of the note.
• Removal should be limited to the resolved litigation. Sun continues to defend related U.S. matters and similar Canadian class actions ^[2], so those exposures would remain separately disclosed if material.

Analytical implication: the upcoming results may show a liability-note clean-up with little or no earnings benefit. A material one-off profit contribution would require evidence that the recorded provision exceeded the final settlement obligation; the disclosed material does not quantify any such excess, so the EPS or PAT impact cannot be estimated reliably.

The resolved Lipitor liability was USD 485 million, but its share of Sun Pharma’s total legal-risk profile cannot be calculated from the cited latest filings. The USD 485 million figure relates to the 2022 settlement of antitrust class actions involving Ranbaxy’s generic-Lipitor conduct ^[3]. The latest exchange update, dated 17 August 2026, reports that the Third Circuit upheld summary judgment for Sun Pharma and denied class certification; it does not quantify either a remaining Lipitor liability or the aggregate value of other legal contingencies ^[4].

If `O` represents the value of other outstanding legal contingent liabilities, the requested ratio would be:

`USD 485 million / (USD 485 million + O) × 100`

Accordingly, the USD 485 million resolution is a material disclosed legal event, but it cannot be compared quantitatively with the broader outstanding legal-risk pool, nor expressed as a percentage of that pool, without the company’s latest contingent-liability total. Also, the settlement amount is historical; it should not automatically be treated as a current balance-sheet liability after the 2026 favorable appellate ruling.